New Centers for Disease Control and Prevention (CDC) data show rising early-season influenza activity, moderate 2024–2025 vaccine effectiveness, and updated 2025–2026 recommendations that include trivalent, thimerosal-free single-dose formulations and expanded access to FluMist.
A new analysis shows thousands of children could contract hepatitis B, leading to further complications and deaths, if the vaccine schedule recommendations are changed to later in a child's life.
Improving public awareness of appropriate antibiotic use could complement antibiotic stewardship programs worldwide.
WHO and UNAIDS warn of service disruptions, widening inequities, and mounting drug-resistance threats, while highlighting innovations and commitments needed to end AIDS as a public health threat.
In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.
The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.
This week, read more about the first person with a novel avian influenza strain, doxyPEP linked to increased high-level tetracycline resistance, Ethiopia investigates Marburg virus disease outbreak, and more.
The World Health Organization (WHO) is assisting Ethiopia with experts, supplies, and emergency funding as the country investigates eight suspected cases of viral hemorrhagic fever in the South Ethiopia region.
James Conway, MD, describes how full vs partial repeal of nonmedical school-entry exemptions is associated with kindergarten vaccination and exemption trends.
Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.
A DOXYVAC substudy found higher rates of tetM-mediated tetracycline resistance and more isolates with decreased cefixime susceptibility among MSM using doxycycline PEP.
This is the first human ever known to be infected with the H5N5 strain. The infected patient was from Washington state, and was undergoing treatment for H5N5 (avian influenza) when the individual died last week.
New modeling and clinical data presented by Atea Pharmaceuticals suggest that its fixed-dose combination of bemnifosbuvir and ruzasvir could offer a potent, short-duration, best-in-class treatment option for hepatitis.
Fewer people are falling ill with TB, and fewer with drug-resistant illness according to the 2025 WHO Global Tuberculosis Report.
The 2025 World Health Organization's (WHO) Global Tuberculosis Report finds progress in prevention, diagnosis, and care—but falling short of targets and curtailed by funding cuts.
This week, read about Merck's advancement of one of its HIV combination therapeutics, Pfizer's influenza vaccine data, the importance of antimicrobial resistance awareness, and more.
Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.
A mother recounts her newborn son's fatal battle with cirrhosis reminding people of the importance of health and education about this vital organ.
Timothy Jenkins, MD, talks about how these important tests are being overly used for respiratory and gastrointestinal presentations and strategies his institution, Denver Health, is employing to reduce testing to save costs and still continuing to achieve optimal treatment outcomes.
David Cameron, PhD, discusses how researchers discovered its antibiotic, Debio 1453, through structure-guided design and advanced it from potent preclinical activity to first-in-human testing.
A review of vaccine safety and effectiveness conducted by the Vaccine Integrity Project, independent of the CDC's ACIP, reflects its stated purpose as "dedicated to safeguarding vaccine use in the US."
Merck’s investigational once-daily, 2-drug HIV regimen, doravirine/islatravir, achieved its primary efficacy and safety end points in a phase 3 trial.
AMR Action Fund CEO Henry Skinner, PhD, MBE, discusses the significance of this week, provides an update on the PASTEUR Act, and explains the differing approaches between Europe and the US with regard to push-pull incentives.
Infectious disease specialists conducted a review of vaccine safety and effectiveness independent of the ACIP to inform vaccinating against COVID-19, RSV, and influenza during this ongoing respiratory virus season.
Kaylee Caniff, PharmD, BCIDP, provides insights on a study looking at how urban and rural healthcare settings differ in terms of prescribing.
This form of prophylaxis showed 79% overall effectiveness across 3 European countries.
Primary completion is expected in Q4 2026 with topline results in Q1 2027, while ECLIPSE 2 and 3 continue enrolling to support potential US and EU submissions.
This week, learn about the first death from a meat allergy caused by ticks, Gilead reports positive top-line data showing its investigational combination therapy, bictegravir/lenacapavir was efficacious and safe, a discussion around antibiotic alternatives for MRSA, and more.
Nathan Shively, MD, talks about the increase of this antibiotic at his institution over the last several years for a variety of infections, particularly osteomyelitis. He also provides insights about dalbavancin's profile including its efficacy and adverse effects.
The Leapfrog Group has released its Fall 2025 Hospital Safety Grades showing states such as Utah and New Jersey remain in the top 5 of rankings. Data on health systems is also included in the report.
